Healthcare / Medical DevicesNasdaqGS
$3.67
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-9.1M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$154M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-77.1%
↓Gross Margin
62.5%
↑Debt/Equity
2.40
↑Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+4.3%
FCF CAGR
—
FCF margin
-17.2%
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $52.8M · net income $-11.2M · FCF $-9.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $52.8M | $52.8M | $48.1M | $52.3M | $44.5M | $48.5M | $27.7M | $28.2M | $16.6M | $10.2M | $8.8M | $29.5M | $27.7M | $23.7M | $27.7M | $25.4M | $24.2M | $27.0M |
| Net Income | $-11.2M | $-11.2M | $-23.5M | $-18.7M | $-23.2M | $-15.2M | $-11.9M | $-19.7M | $62.7M | $-5.1M | $-11.6M | $-5.4M | $-17.3M | $-4.3M | $617000.00 | $109000.00 | $-1.5M | $596000.00 |
| EBITDA | $-5.8M | $-5.8M | $-18.2M | $-16.6M | $-22.7M | $-13.5M | $-19.2M | $-20.1M | $-13.6M | $-13.2M | $-10.7M | $-6.2M | $-5.0M | $-2.8M | $1.8M | $735000.00 | $-2.0M | $1.5M |
| EPS | -0.27 | -0.27 | -0.66 | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.83 | -0.17 | -0.15 | 0.24 | -1.03 | -0.40 | 0.03 | 0.01 | -0.09 | 0.03 |
| Gross Margin | 62.5% | 62.5% | 61.0% | 64.5% | 65.4% | 69.3% | 63.2% | 67.6% | 65.2% | 68.0% | 58.0% | 42.5% | 32.5% | 38.9% | 41.0% | 42.2% | 41.2% | 44.0% |
| Operating Margin | -12.2% | -12.2% | -39.2% | -33.0% | -52.9% | -29.8% | -72.5% | -73.9% | -86.0% | -135.7% | -129.2% | -23.7% | -21.1% | -15.5% | 3.8% | -0.1% | -11.4% | 2.7% |
| Net Margin | -21.2% | -21.2% | -48.8% | -35.7% | -52.1% | -31.3% | -42.9% | -69.8% | 377.7% | -49.5% | -131.0% | -18.2% | -62.4% | -18.3% | 2.2% | 0.4% | -6.3% | 2.2% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 2.40 | 2.40 | 2.39 | 1.24 | 0.00 | — | — | — | 0.00 | 0.11 | 0.10 | 0.13 | — | 0.17 | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-9.1M | $-9.1M | $-18.8M | $-5.8M | $-21.3M | $-11.2M | $-16.6M | $-19.8M | $-21.2M | $-4.3M | $-3.1M | $-6.2M | $-1.0M | $-3.1M | $-588000.00 | $1.4M | $-727000.00 | $-2.6M |
| Returns | ||||||||||||||||||
| ROE | -77.1% | -77.1% | -165.1% | -70.1% | -61.7% | -28.3% | -18.7% | -27.7% | 71.9% | -23.0% | -44.0% | -22.9% | -1149.1% | -22.8% | 2.7% | 0.5% | -7.1% | 2.8% |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 9.9% | 9.9% | -8.1% | 17.6% | -8.3% | 75.1% | -1.9% | 70.0% | 62.3% | 16.0% | -70.1% | 6.6% | 17.0% | -14.5% | 8.9% | 4.9% | -10.1% | — |
| EPS Growth | 59.1% | 59.1% | -22.2% | 19.4% | -52.3% | -25.7% | 39.7% | -131.7% | 1176.5% | -13.3% | -162.5% | 123.3% | -157.5% | -1433.3% | 200.0% | 111.1% | -400.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.